Jasper Therapeutics reports Phase 1 briquilimab data: all 12 patients engrafted; appoints Vishal Kapoor to board

Jasper Therapeutics, Inc.

Appointed Vishal Kapoor to board effective Feb 16, 2023; he is Partner at Avego Management and received option for 109,383 shares at $1.83.
Phase 1 briquilimab data: 12/12 AML patients achieved neutrophil engraftment at median 19 days; no briquilimab-related SAEs.
12 patients at Stanford treated outpatient; all discharged same day (zero inpatient days); mean inpatient stay over first 100 days was 4 days.
Addition of briquilimab to conditioning regimen does not appear to increase GVHD incidence relative to published rates.

item 5.02 item 5.03 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vishal Kapoor

Class I Director

JSPR · Jasper Therapeutics, Inc.

Effective: 2023-02-16
Filed: February 17, 2023, 6:59 PM ET

Effective February 16, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Vishal Kapoor as a Class I director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vishal Kapoor was appointed as Class I Director at Jasper Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

Effective February 16, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Vishal Kapoor as a Class I director of the Company.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Jasper Therapeutics, Inc.: Adopted third amended and restated bylaws to address universal proxy rules and enhance disclosure requirements for director nominations and business proposals by stockholders (effective 2023-02-16).

Change: bylaw amendment
Effective: 2023-02-16

Exact text from the filing

On and effective February 16, 2023, the Board approved and adopted an amendment and restatement of the Company’s second amended and restated bylaws (as so amended and restated, the “Third Amended and Restated Bylaws”), effective as of February 16, 2023.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-012596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.